Therefore, the OROME score perfectly captures the benefits of SGLT2i in HF (Santos-Gallego et al., 2021) given that higher levels of omentin and lower levels of orosomucoid both predict improved outcomes (as per the OROME score) and are also a consequence of SGLT2i treatment (as demonstrated in Requena-Ibáñez et al. (2021). The gene discussed is ITLN1; the disease is hydrops fetalis.